A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
The “2022 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs.
Israel’s Belkin Vision announced May 16 that its Eagle automated laser treatment for glaucoma received CE marking. The Eagle is the first contactless laser for glaucoma. Controlled rollout of the s...
Israel’s Teva Pharmaceutical Industries announced May 17 that the UK’s Medicines & Healthcare Regulatory Agency (MHRA) had granted marketing approval to Ongavia, a Lucentis (ranibizumab) biosimilar...
Visionix, formerly Luneau Technology, and Japan’s Right MFG announced May 16 that they had entered a long-term strategic partnership agreement. Financial terms of the deal were not disclosed. Visio...
Cannabis companies Skye Bioscience and Emerald Health Therapeutics announced May 12 that they had signed a deal for Skye to acquire all shares of Emerald in a share-for-share transaction that inclu...
Brim Biotechnology, of Taiwan, announced May 17 that it had partnered with ophthalmic research company Ora on a Phase III clinical trial, set to begin in Q4-2022, for Brim’s lead drug candidate, BR...
Formosa Pharmaceuticals and AimMax Therapeutics reported positive results May 12 from the first of two pivotal Phase III studies of APP13007, a novel ophthalmic nanosuspension of the corticosteroid...
Visiox Pharma, which is advancing new formulations of well-known ophthalmic compounds, announced May 17 that it had appointed Ryan S. Bleeks as chief executive officer. Previously, Bleeks was vice ...
Visus Therapeutics announced May 11 that Hong Kong’s Zhaoke Ophthalmology had signed an exclusive licensing agreement for the development and commercialization of presbyopia drop candidates Brimoch...
On average, our surveys take only 5 to 15 minutes to complete. Survey results help you analyze practice patterns, evaluate treatment choices, and benchmark your practice.
Benchmark reports allow you to gauge your performance, track your practice metrics over time, and compare your practice to national averages.
Additional free data tools include instant survey results, weekly polls, PowerPoint charts, and more.
Learn More Register TodayA Multi-Step Approach for Accurate & Timely Data
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.